熱門資訊> 正文

KalVista Pharmaceuticals超出第四季度预期

2026-03-25 19:09

KalVista Pharmaceuticals press release (KALV): Q4 GAAP EPS of -$2.03 may not be comparable to estimates.
Revenue of $49.08M beats by $16.79M.
As of December 31, 2025, the Company had cash, cash equivalents and marketable securities of approximately $300.2 million. We anticipate that cash, cash equivalents and marketable securities as of December 31, 2025, along with projected revenues associated with the sale of EKTERLY will fund the Company through profitability.

More on KalVista Pharmaceuticals

KalVista Pharmaceuticals: Has Potential But With Caveats
KalVista: Next Stage Of Growth For EKTERLY Lies With Pediatric Label Expansion
KalVista Pharmaceuticals Q4 2025 Earnings Preview
Quant snapshot: AAR, Noah Holdings lead strong buys as Blaize, Fractyl Health lag
Seeking Alpha’s Quant Rating on KalVista Pharmaceuticals

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。